| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leiomyoma | 31 | 2026 | 33 | 19.850 |
Why?
|
| Uterine Neoplasms | 25 | 2026 | 29 | 13.670 |
Why?
|
| MicroRNAs | 22 | 2026 | 54 | 9.280 |
Why?
|
| RNA, Long Noncoding | 13 | 2026 | 20 | 7.500 |
Why?
|
| Gene Expression Regulation, Neoplastic | 17 | 2026 | 88 | 6.080 |
Why?
|
| Female | 95 | 2026 | 4060 | 4.050 |
Why?
|
| Cell Proliferation | 11 | 2026 | 143 | 3.390 |
Why?
|
| Humans | 67 | 2026 | 6794 | 2.960 |
Why?
|
| Myometrium | 10 | 2026 | 11 | 2.840 |
Why?
|
| Transcriptome | 3 | 2026 | 31 | 2.710 |
Why?
|
| Myocytes, Smooth Muscle | 7 | 2024 | 27 | 2.480 |
Why?
|
| Animals | 58 | 2026 | 1875 | 2.060 |
Why?
|
| Mediator Complex | 4 | 2025 | 4 | 2.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 12 | 2026 | 93 | 2.000 |
Why?
|
| Epigenesis, Genetic | 6 | 2019 | 36 | 1.910 |
Why?
|
| Endometrium | 9 | 2012 | 24 | 1.860 |
Why?
|
| Adult | 27 | 2025 | 2113 | 1.810 |
Why?
|
| Malnutrition | 7 | 2014 | 51 | 1.810 |
Why?
|
| Muscle, Smooth, Vascular | 7 | 2017 | 31 | 1.800 |
Why?
|
| Transforming Growth Factor beta3 | 3 | 2023 | 3 | 1.630 |
Why?
|
| Glucocorticoids | 7 | 2018 | 65 | 1.630 |
Why?
|
| Middle Aged | 20 | 2025 | 2108 | 1.520 |
Why?
|
| RNA, Messenger | 13 | 2023 | 190 | 1.490 |
Why?
|
| RNA, Small Untranslated | 2 | 2025 | 2 | 1.460 |
Why?
|
| ortho-Aminobenzoates | 3 | 2023 | 3 | 1.350 |
Why?
|
| Gene Expression Profiling | 6 | 2026 | 44 | 1.350 |
Why?
|
| Signal Transduction | 7 | 2026 | 246 | 1.240 |
Why?
|
| Postmenopause | 4 | 2025 | 10 | 1.150 |
Why?
|
| Nitric Oxide | 6 | 2008 | 47 | 1.140 |
Why?
|
| Extracellular Matrix | 3 | 2021 | 22 | 1.120 |
Why?
|
| Tryptophan | 3 | 2023 | 5 | 1.090 |
Why?
|
| Mice | 6 | 2026 | 746 | 1.090 |
Why?
|
| Nitric Oxide Synthase | 5 | 2008 | 39 | 1.070 |
Why?
|
| Pregnancy | 26 | 2026 | 599 | 1.070 |
Why?
|
| Aging | 11 | 2011 | 105 | 1.060 |
Why?
|
| Rats | 35 | 2026 | 571 | 1.050 |
Why?
|
| Premenopause | 3 | 2025 | 6 | 1.040 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 22 | 0.990 |
Why?
|
| Neovascularization, Physiologic | 3 | 2013 | 8 | 0.990 |
Why?
|
| Fetal Nutrition Disorders | 3 | 2015 | 9 | 0.980 |
Why?
|
| Dexamethasone | 2 | 2017 | 30 | 0.980 |
Why?
|
| Extracellular Vesicles | 1 | 2026 | 6 | 0.970 |
Why?
|
| Exosomes | 1 | 2026 | 7 | 0.970 |
Why?
|
| Extracellular Matrix Proteins | 3 | 2018 | 8 | 0.950 |
Why?
|
| Mutation | 5 | 2025 | 97 | 0.950 |
Why?
|
| RNA, Untranslated | 1 | 2025 | 2 | 0.930 |
Why?
|
| Cytokines | 2 | 2024 | 80 | 0.930 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2025 | 23 | 0.900 |
Why?
|
| Transcription Factor RelA | 3 | 2020 | 7 | 0.860 |
Why?
|
| DNA Methylation | 3 | 2019 | 26 | 0.860 |
Why?
|
| Nitriles | 1 | 2024 | 13 | 0.860 |
Why?
|
| Sulfones | 1 | 2024 | 10 | 0.860 |
Why?
|
| Mice, SCID | 4 | 2024 | 16 | 0.850 |
Why?
|
| Dioxygenases | 1 | 2023 | 2 | 0.830 |
Why?
|
| Indoles | 1 | 2023 | 11 | 0.830 |
Why?
|
| Transcription, Genetic | 4 | 2017 | 40 | 0.810 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2026 | 282 | 0.800 |
Why?
|
| Cells, Cultured | 10 | 2021 | 234 | 0.790 |
Why?
|
| Ovary | 3 | 2014 | 19 | 0.790 |
Why?
|
| Amino Acid Transport Systems, Neutral | 1 | 2022 | 1 | 0.740 |
Why?
|
| Interleukin-8 | 4 | 2020 | 10 | 0.720 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2021 | 2 | 0.700 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2026 | 38 | 0.660 |
Why?
|
| Progesterone | 3 | 2015 | 14 | 0.650 |
Why?
|
| Tumor Cells, Cultured | 5 | 2021 | 72 | 0.650 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2013 | 30 | 0.640 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 156 | 0.640 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 25 | 0.630 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2019 | 3 | 0.630 |
Why?
|
| Epithelial Cells | 3 | 2008 | 49 | 0.630 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2012 | 13 | 0.620 |
Why?
|
| Melanocyte-Stimulating Hormones | 13 | 1987 | 13 | 0.610 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2021 | 17 | 0.610 |
Why?
|
| Fetal Growth Retardation | 4 | 2018 | 42 | 0.600 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 72 | 0.600 |
Why?
|
| Transcription Factors | 3 | 2024 | 53 | 0.590 |
Why?
|
| Hypothalamo-Hypophyseal System | 5 | 2014 | 18 | 0.580 |
Why?
|
| Endothelium, Vascular | 4 | 2013 | 30 | 0.580 |
Why?
|
| Pregnancy Complications | 2 | 2010 | 44 | 0.550 |
Why?
|
| I-kappa B Kinase | 2 | 2014 | 5 | 0.540 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 120 | 0.530 |
Why?
|
| Disease Models, Animal | 5 | 2024 | 231 | 0.530 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2012 | 90 | 0.530 |
Why?
|
| Down-Regulation | 5 | 2021 | 57 | 0.520 |
Why?
|
| Hypothalamus | 13 | 1989 | 49 | 0.520 |
Why?
|
| Male | 30 | 2026 | 3671 | 0.520 |
Why?
|
| Anti-Allergic Agents | 1 | 2016 | 2 | 0.510 |
Why?
|
| Corticosterone | 2 | 2015 | 24 | 0.480 |
Why?
|
| Carotid Arteries | 1 | 2015 | 4 | 0.460 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2015 | 16 | 0.450 |
Why?
|
| Carrier Proteins | 3 | 2023 | 28 | 0.450 |
Why?
|
| Aorta | 3 | 2010 | 20 | 0.450 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2015 | 155 | 0.450 |
Why?
|
| Menopause, Premature | 1 | 2014 | 2 | 0.440 |
Why?
|
| Leiomyosarcoma | 1 | 2014 | 1 | 0.440 |
Why?
|
| Menstrual Cycle | 5 | 2006 | 11 | 0.440 |
Why?
|
| Gene Knockdown Techniques | 2 | 2024 | 9 | 0.440 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 4 | 0.430 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 30 | 0.430 |
Why?
|
| Hysterectomy | 3 | 2021 | 12 | 0.420 |
Why?
|
| Fetal Development | 2 | 2013 | 28 | 0.410 |
Why?
|
| Prolactin | 16 | 1991 | 23 | 0.410 |
Why?
|
| Cyclin-Dependent Kinase 2 | 3 | 2020 | 4 | 0.410 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2013 | 20 | 0.410 |
Why?
|
| Blood Vessels | 1 | 2013 | 3 | 0.410 |
Why?
|
| Nicotine | 3 | 2026 | 144 | 0.400 |
Why?
|
| Genitalia, Female | 2 | 2004 | 3 | 0.400 |
Why?
|
| Myocardium | 2 | 2026 | 25 | 0.400 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2002 | 12 | 0.400 |
Why?
|
| Receptors, Aryl Hydrocarbon | 2 | 2004 | 3 | 0.400 |
Why?
|
| Gene Expression | 3 | 2018 | 77 | 0.400 |
Why?
|
| Collagen Type III | 4 | 2020 | 5 | 0.390 |
Why?
|
| Inflammation | 1 | 2014 | 143 | 0.390 |
Why?
|
| Infertility, Female | 2 | 2012 | 18 | 0.380 |
Why?
|
| Abortion, Habitual | 1 | 2012 | 1 | 0.380 |
Why?
|
| Dehydroepiandrosterone | 3 | 1997 | 6 | 0.370 |
Why?
|
| Testosterone | 4 | 2014 | 50 | 0.360 |
Why?
|
| Genital Neoplasms, Female | 2 | 2002 | 9 | 0.350 |
Why?
|
| Blastocyst | 2 | 2002 | 5 | 0.350 |
Why?
|
| Metyrapone | 4 | 2018 | 7 | 0.350 |
Why?
|
| Growth Hormone-Releasing Hormone | 3 | 2001 | 4 | 0.350 |
Why?
|
| Food Deprivation | 1 | 2011 | 7 | 0.350 |
Why?
|
| Uterus | 2 | 2002 | 15 | 0.350 |
Why?
|
| Steroids | 1 | 2011 | 8 | 0.350 |
Why?
|
| Adrenal Glands | 1 | 2011 | 11 | 0.350 |
Why?
|
| Transfection | 3 | 2015 | 56 | 0.340 |
Why?
|
| Spermatozoa | 3 | 2006 | 9 | 0.340 |
Why?
|
| Menopause | 2 | 2001 | 4 | 0.330 |
Why?
|
| Luteinizing Hormone | 12 | 1989 | 19 | 0.330 |
Why?
|
| Growth Hormone | 7 | 2001 | 25 | 0.330 |
Why?
|
| Animals, Newborn | 7 | 2020 | 112 | 0.320 |
Why?
|
| Endometriosis | 3 | 2002 | 6 | 0.320 |
Why?
|
| Pituitary Gland | 9 | 1988 | 40 | 0.320 |
Why?
|
| NF-kappa B | 2 | 2024 | 56 | 0.320 |
Why?
|
| Lung | 3 | 2018 | 106 | 0.320 |
Why?
|
| Caloric Restriction | 3 | 2014 | 13 | 0.310 |
Why?
|
| Immune System | 2 | 2001 | 14 | 0.300 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 3 | 2014 | 25 | 0.300 |
Why?
|
| Cell Movement | 3 | 2018 | 38 | 0.300 |
Why?
|
| Semen | 2 | 2006 | 3 | 0.300 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2006 | 20 | 0.290 |
Why?
|
| Smoke | 1 | 2008 | 6 | 0.290 |
Why?
|
| Tobacco | 1 | 2008 | 3 | 0.290 |
Why?
|
| Flow Cytometry | 3 | 2024 | 48 | 0.290 |
Why?
|
| Apoptosis | 2 | 2024 | 179 | 0.290 |
Why?
|
| Androgens | 2 | 2014 | 24 | 0.280 |
Why?
|
| Phosphorylation | 3 | 2015 | 73 | 0.280 |
Why?
|
| Sermorelin | 2 | 1997 | 2 | 0.270 |
Why?
|
| Vascular Diseases | 1 | 2007 | 10 | 0.260 |
Why?
|
| Ventricular Remodeling | 1 | 2007 | 5 | 0.260 |
Why?
|
| Estradiol | 7 | 2015 | 57 | 0.250 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2006 | 1 | 0.250 |
Why?
|
| Clomiphene | 1 | 2006 | 1 | 0.240 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2006 | 5 | 0.240 |
Why?
|
| Ovulation | 1 | 2006 | 5 | 0.240 |
Why?
|
| Ovulation Induction | 1 | 2006 | 5 | 0.240 |
Why?
|
| Heart | 1 | 2026 | 25 | 0.240 |
Why?
|
| Immunohistochemistry | 4 | 2012 | 118 | 0.240 |
Why?
|
| Time Factors | 6 | 2015 | 321 | 0.240 |
Why?
|
| Metformin | 1 | 2006 | 35 | 0.230 |
Why?
|
| Hypertension | 1 | 2007 | 147 | 0.230 |
Why?
|
| Estrogens | 1 | 2005 | 27 | 0.230 |
Why?
|
| Elastin | 2 | 2015 | 4 | 0.230 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2015 | 8 | 0.230 |
Why?
|
| Infertility, Male | 2 | 2004 | 6 | 0.230 |
Why?
|
| Nicotinic Agonists | 2 | 2020 | 38 | 0.230 |
Why?
|
| Embryo Implantation | 2 | 2002 | 8 | 0.230 |
Why?
|
| Binding Sites | 2 | 2015 | 24 | 0.220 |
Why?
|
| Luciferases | 1 | 2004 | 10 | 0.220 |
Why?
|
| Placenta | 2 | 2002 | 58 | 0.220 |
Why?
|
| Urinary Tract Physiological Phenomena | 1 | 2004 | 1 | 0.220 |
Why?
|
| Adenosine Monophosphate | 1 | 2004 | 4 | 0.220 |
Why?
|
| Caspase 7 | 2 | 2014 | 3 | 0.220 |
Why?
|
| Neuropeptide Y | 4 | 1989 | 13 | 0.220 |
Why?
|
| Mast Cells | 1 | 2024 | 2 | 0.220 |
Why?
|
| Caspase 3 | 2 | 2014 | 27 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 45 | 0.210 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 35 | 0.210 |
Why?
|
| Immunity | 3 | 2001 | 3 | 0.210 |
Why?
|
| Macrophages | 1 | 2024 | 40 | 0.210 |
Why?
|
| Kynurenine | 1 | 2023 | 3 | 0.210 |
Why?
|
| Tryptophan Oxygenase | 1 | 2023 | 2 | 0.210 |
Why?
|
| Age Factors | 7 | 2020 | 193 | 0.210 |
Why?
|
| Collagen | 1 | 2023 | 31 | 0.210 |
Why?
|
| Cell Culture Techniques | 2 | 2017 | 18 | 0.200 |
Why?
|
| SOXC Transcription Factors | 1 | 2023 | 1 | 0.200 |
Why?
|
| Genes, cdc | 1 | 2023 | 3 | 0.200 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2023 | 4 | 0.200 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 17 | 0.200 |
Why?
|
| Serotonin | 2 | 2022 | 5 | 0.200 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2003 | 4 | 0.200 |
Why?
|
| DNA Mutational Analysis | 1 | 2023 | 15 | 0.200 |
Why?
|
| RNA | 1 | 2023 | 25 | 0.190 |
Why?
|
| Aged | 8 | 2002 | 1539 | 0.190 |
Why?
|
| Hypoxia | 2 | 2013 | 37 | 0.190 |
Why?
|
| Cell Line | 2 | 2017 | 124 | 0.190 |
Why?
|
| Pituitary Gland, Anterior | 10 | 1986 | 17 | 0.190 |
Why?
|
| Receptors, Vitronectin | 1 | 2002 | 1 | 0.190 |
Why?
|
| Pregnancy, Multiple | 1 | 2002 | 2 | 0.190 |
Why?
|
| Ligases | 1 | 2022 | 1 | 0.190 |
Why?
|
| Polycomb-Group Proteins | 1 | 2022 | 1 | 0.190 |
Why?
|
| Kynurenic Acid | 1 | 2022 | 1 | 0.190 |
Why?
|
| Fibroblasts | 2 | 2020 | 53 | 0.190 |
Why?
|
| NAD | 1 | 2022 | 3 | 0.190 |
Why?
|
| Rats, Inbred Strains | 19 | 1991 | 49 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2008 | 26 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2012 | 14 | 0.180 |
Why?
|
| Ascitic Fluid | 3 | 2002 | 6 | 0.180 |
Why?
|
| Multigene Family | 1 | 2021 | 6 | 0.180 |
Why?
|
| Protein Multimerization | 1 | 2021 | 3 | 0.180 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 38 | 0.180 |
Why?
|
| Body Composition | 5 | 2014 | 47 | 0.180 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2001 | 2 | 0.180 |
Why?
|
| Reproductive Techniques | 1 | 2001 | 2 | 0.170 |
Why?
|
| Receptors, Progesterone | 1 | 2021 | 11 | 0.170 |
Why?
|
| Collagen Type I | 2 | 2020 | 18 | 0.170 |
Why?
|
| Sex Characteristics | 3 | 1997 | 39 | 0.170 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 10 | 0.170 |
Why?
|
| Follicle Stimulating Hormone | 7 | 1989 | 15 | 0.170 |
Why?
|
| Fibrosis | 2 | 2020 | 53 | 0.170 |
Why?
|
| Human Growth Hormone | 2 | 1997 | 7 | 0.170 |
Why?
|
| Embryo Transfer | 1 | 2000 | 5 | 0.160 |
Why?
|
| Heart Diseases | 1 | 2020 | 9 | 0.160 |
Why?
|
| Fertilization in Vitro | 1 | 2000 | 19 | 0.160 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 70 | 0.160 |
Why?
|
| Base Sequence | 2 | 2014 | 65 | 0.160 |
Why?
|
| Epithelium | 2 | 2012 | 22 | 0.140 |
Why?
|
| Stromal Cells | 2 | 2012 | 10 | 0.140 |
Why?
|
| Cyclin D1 | 1 | 2018 | 4 | 0.140 |
Why?
|
| Radioimmunoassay | 9 | 2006 | 26 | 0.130 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 26 | 0.130 |
Why?
|
| Arterioles | 2 | 2007 | 8 | 0.130 |
Why?
|
| Birth Weight | 2 | 2007 | 33 | 0.130 |
Why?
|
| Ovariectomy | 6 | 2014 | 19 | 0.130 |
Why?
|
| Gonadotropin-Releasing Hormone | 6 | 1989 | 8 | 0.120 |
Why?
|
| Cell Differentiation | 2 | 2014 | 101 | 0.120 |
Why?
|
| Biomarkers | 2 | 2013 | 214 | 0.120 |
Why?
|
| Phenotype | 3 | 2026 | 91 | 0.120 |
Why?
|
| Sp1 Transcription Factor | 1 | 2015 | 3 | 0.120 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2015 | 3 | 0.120 |
Why?
|
| Sheep | 3 | 2012 | 132 | 0.120 |
Why?
|
| RNA Interference | 1 | 2015 | 11 | 0.120 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 1 | 0.120 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 2 | 0.120 |
Why?
|
| Collagen Type IV | 1 | 2015 | 4 | 0.120 |
Why?
|
| Cardiovascular Diseases | 2 | 2014 | 172 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2015 | 94 | 0.110 |
Why?
|
| Cyclins | 1 | 2014 | 7 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2008 | 110 | 0.110 |
Why?
|
| Sexuality | 1 | 2014 | 16 | 0.110 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2014 | 9 | 0.110 |
Why?
|
| Obesity | 2 | 2007 | 226 | 0.100 |
Why?
|
| Cerebrovascular Circulation | 1 | 2014 | 9 | 0.100 |
Why?
|
| Lymphokines | 1 | 1993 | 8 | 0.100 |
Why?
|
| Somatostatin | 6 | 1987 | 10 | 0.100 |
Why?
|
| Steroid Synthesis Inhibitors | 1 | 2013 | 2 | 0.100 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2013 | 5 | 0.100 |
Why?
|
| Nutritional Status | 1 | 2014 | 64 | 0.100 |
Why?
|
| Bleomycin | 1 | 1993 | 1 | 0.100 |
Why?
|
| Lymphocele | 1 | 1993 | 1 | 0.100 |
Why?
|
| Sclerotherapy | 1 | 1993 | 1 | 0.100 |
Why?
|
| Inguinal Canal | 1 | 1993 | 2 | 0.100 |
Why?
|
| Infant, Premature | 1 | 2013 | 23 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 34 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2013 | 17 | 0.100 |
Why?
|
| Endorphins | 4 | 1987 | 4 | 0.100 |
Why?
|
| Dopamine | 6 | 1986 | 12 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2013 | 199 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 1997 | 14 | 0.100 |
Why?
|
| Median Eminence | 6 | 1991 | 7 | 0.100 |
Why?
|
| Myosin Heavy Chains | 1 | 2012 | 6 | 0.100 |
Why?
|
| Arteries | 1 | 2012 | 15 | 0.100 |
Why?
|
| Stress, Physiological | 4 | 1985 | 19 | 0.090 |
Why?
|
| Kinetics | 5 | 1997 | 69 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2011 | 5 | 0.090 |
Why?
|
| Contractile Proteins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2011 | 1 | 0.090 |
Why?
|
| Ovarian Neoplasms | 2 | 2002 | 35 | 0.090 |
Why?
|
| Brain | 5 | 1996 | 94 | 0.090 |
Why?
|
| Sperm Injections, Intracytoplasmic | 2 | 2001 | 3 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2004 | 108 | 0.080 |
Why?
|
| Pituitary Hormones, Anterior | 2 | 1987 | 3 | 0.080 |
Why?
|
| B-Lymphocytes | 2 | 2001 | 9 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2001 | 20 | 0.080 |
Why?
|
| Lactation | 2 | 1986 | 11 | 0.080 |
Why?
|
| Reference Values | 3 | 2007 | 56 | 0.080 |
Why?
|
| Estrus | 3 | 1985 | 4 | 0.070 |
Why?
|
| Prolactin Release-Inhibiting Factors | 2 | 1986 | 2 | 0.070 |
Why?
|
| Benzo(a)pyrene | 1 | 2008 | 2 | 0.070 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 3 | 0.070 |
Why?
|
| Follicular Phase | 1 | 2008 | 3 | 0.070 |
Why?
|
| Glutathione | 1 | 2008 | 14 | 0.070 |
Why?
|
| Arginine | 1 | 2008 | 20 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2008 | 30 | 0.070 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2008 | 4 | 0.070 |
Why?
|
| Antioxidants | 1 | 2008 | 37 | 0.070 |
Why?
|
| Periodicity | 2 | 1997 | 8 | 0.070 |
Why?
|
| Lymphocyte Subsets | 2 | 1997 | 5 | 0.070 |
Why?
|
| Splanchnic Circulation | 1 | 2007 | 3 | 0.070 |
Why?
|
| Vascular Resistance | 1 | 2007 | 7 | 0.070 |
Why?
|
| Mesenteric Arteries | 1 | 2007 | 6 | 0.070 |
Why?
|
| Gestational Age | 2 | 2020 | 58 | 0.070 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 1 | 1987 | 1 | 0.070 |
Why?
|
| Macaca mulatta | 2 | 2002 | 8 | 0.060 |
Why?
|
| Limbic System | 1 | 1987 | 2 | 0.060 |
Why?
|
| Alzheimer Disease | 1 | 2007 | 30 | 0.060 |
Why?
|
| Hormone Antagonists | 1 | 2006 | 4 | 0.060 |
Why?
|
| Glycogen | 1 | 2006 | 10 | 0.060 |
Why?
|
| Mifepristone | 1 | 2006 | 8 | 0.060 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2006 | 10 | 0.060 |
Why?
|
| Rabbits | 6 | 1989 | 48 | 0.060 |
Why?
|
| Fertility Agents, Female | 1 | 2006 | 1 | 0.060 |
Why?
|
| Hyperinsulinism | 1 | 2006 | 6 | 0.060 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2026 | 2 | 0.060 |
Why?
|
| Sperm Motility | 1 | 2006 | 2 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2006 | 20 | 0.060 |
Why?
|
| Cell Count | 1 | 2006 | 18 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 50 | 0.060 |
Why?
|
| Biogenic Amines | 1 | 1986 | 1 | 0.060 |
Why?
|
| Infertility | 1 | 2006 | 11 | 0.060 |
Why?
|
| Diet | 1 | 2007 | 111 | 0.060 |
Why?
|
| Estrogen Antagonists | 1 | 2005 | 5 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 15 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 38 | 0.060 |
Why?
|
| Liver | 2 | 2008 | 157 | 0.060 |
Why?
|
| Injections, Intraventricular | 6 | 1989 | 21 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2005 | 10 | 0.060 |
Why?
|
| Insulin | 1 | 2006 | 146 | 0.060 |
Why?
|
| Fetus | 3 | 2012 | 125 | 0.060 |
Why?
|
| Urinary Tract | 1 | 2004 | 1 | 0.060 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2004 | 2 | 0.060 |
Why?
|
| Postpartum Period | 1 | 1984 | 14 | 0.060 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2004 | 2 | 0.060 |
Why?
|
| Pregnancy, Animal | 1 | 1984 | 15 | 0.050 |
Why?
|
| Neurotransmitter Agents | 1 | 2004 | 5 | 0.050 |
Why?
|
| Urethra | 1 | 2004 | 7 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2004 | 13 | 0.050 |
Why?
|
| Cystitis | 1 | 2004 | 4 | 0.050 |
Why?
|
| Spinal Cord Injuries | 1 | 2004 | 8 | 0.050 |
Why?
|
| Dioxins | 1 | 2004 | 1 | 0.050 |
Why?
|
| Hydrocarbons | 1 | 2004 | 1 | 0.050 |
Why?
|
| ARNTL Transcription Factors | 1 | 2004 | 1 | 0.050 |
Why?
|
| Spectrophotometry | 1 | 2004 | 2 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2004 | 9 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 23 | 0.050 |
Why?
|
| Protein Binding | 1 | 2004 | 29 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 165 | 0.050 |
Why?
|
| In Vitro Techniques | 5 | 1988 | 72 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2006 | 500 | 0.050 |
Why?
|
| Immune Sera | 5 | 1986 | 5 | 0.050 |
Why?
|
| Age Determination by Skeleton | 1 | 2003 | 1 | 0.050 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2003 | 1 | 0.050 |
Why?
|
| Ovarian Function Tests | 1 | 2003 | 1 | 0.050 |
Why?
|
| Growth | 1 | 2003 | 2 | 0.050 |
Why?
|
| Castration | 6 | 1985 | 13 | 0.050 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2003 | 7 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2004 | 285 | 0.050 |
Why?
|
| Pregnancy Reduction, Multifetal | 1 | 2002 | 1 | 0.050 |
Why?
|
| Biopsy | 1 | 2002 | 36 | 0.050 |
Why?
|
| Risk Factors | 2 | 2005 | 767 | 0.050 |
Why?
|
| Spiperone | 5 | 1986 | 5 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 208 | 0.050 |
Why?
|
| Fallopian Tubes | 1 | 2002 | 1 | 0.050 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2002 | 1 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2005 | 681 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2002 | 27 | 0.050 |
Why?
|
| Hirsutism | 1 | 2001 | 4 | 0.050 |
Why?
|
| Acne Vulgaris | 1 | 2001 | 4 | 0.050 |
Why?
|
| Safety | 1 | 2001 | 18 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2001 | 33 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2001 | 16 | 0.040 |
Why?
|
| Granulocytes | 1 | 2001 | 2 | 0.040 |
Why?
|
| Cognition | 1 | 2001 | 30 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2001 | 2 | 0.040 |
Why?
|
| Monocytes | 1 | 2001 | 14 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2001 | 3 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2001 | 2 | 0.040 |
Why?
|
| Endometrial Neoplasms | 1 | 2001 | 25 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2001 | 50 | 0.040 |
Why?
|
| Pregnancy Rate | 1 | 2000 | 5 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 1997 | 12 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 1997 | 6 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 1997 | 2 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 1997 | 2 | 0.030 |
Why?
|
| Skinfold Thickness | 1 | 1997 | 3 | 0.030 |
Why?
|
| Placebos | 1 | 1997 | 10 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 1997 | 11 | 0.030 |
Why?
|
| Cerebral Ventricles | 2 | 1989 | 5 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1997 | 13 | 0.030 |
Why?
|
| Hormones | 1 | 1997 | 11 | 0.030 |
Why?
|
| Thyrotropin-Releasing Hormone | 3 | 1986 | 19 | 0.030 |
Why?
|
| Bone Density | 1 | 1996 | 25 | 0.030 |
Why?
|
| Hypothalamus, Middle | 2 | 1986 | 2 | 0.030 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1995 | 5 | 0.030 |
Why?
|
| Muscles | 1 | 1995 | 19 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1995 | 25 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 1995 | 27 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1995 | 54 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 1995 | 101 | 0.030 |
Why?
|
| Fever | 2 | 1986 | 7 | 0.030 |
Why?
|
| Neoplasms | 1 | 1996 | 92 | 0.030 |
Why?
|
| Suprachiasmatic Nucleus | 2 | 1985 | 2 | 0.030 |
Why?
|
| Preoptic Area | 2 | 1985 | 3 | 0.030 |
Why?
|
| Substance P | 2 | 1985 | 9 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2014 | 5 | 0.030 |
Why?
|
| Arousal | 1 | 2014 | 3 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2014 | 9 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 13 | 0.030 |
Why?
|
| Tissue Extracts | 2 | 1984 | 3 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2014 | 1 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2014 | 8 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 1993 | 4 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 53 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 1993 | 23 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 1 | 2013 | 3 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2013 | 5 | 0.030 |
Why?
|
| Phospholipids | 1 | 2013 | 6 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 75 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 1993 | 7 | 0.030 |
Why?
|
| Drainage | 1 | 1993 | 10 | 0.030 |
Why?
|
| Weight Gain | 1 | 2013 | 28 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2014 | 100 | 0.030 |
Why?
|
| Calcium | 1 | 2014 | 117 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 155 | 0.020 |
Why?
|
| Phthalazines | 1 | 2012 | 1 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 23 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 17 | 0.020 |
Why?
|
| Pyridines | 1 | 2012 | 24 | 0.020 |
Why?
|
| Oxygen | 1 | 2012 | 44 | 0.020 |
Why?
|
| beta-Endorphin | 3 | 1987 | 15 | 0.020 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2011 | 1 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 1 | 0.020 |
Why?
|
| Myosin Light Chains | 1 | 2011 | 2 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2011 | 2 | 0.020 |
Why?
|
| Tunica Media | 1 | 2011 | 2 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 5 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2011 | 9 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 2011 | 13 | 0.020 |
Why?
|
| Actins | 1 | 2011 | 28 | 0.020 |
Why?
|
| Potassium | 1 | 2011 | 26 | 0.020 |
Why?
|
| alpha-MSH | 1 | 1991 | 3 | 0.020 |
Why?
|
| Neurons | 1 | 1991 | 50 | 0.020 |
Why?
|
| Chromatography, Gel | 2 | 1987 | 2 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1989 | 1 | 0.020 |
Why?
|
| Copper | 1 | 1989 | 2 | 0.020 |
Why?
|
| Norepinephrine | 2 | 1986 | 10 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 1987 | 25 | 0.020 |
Why?
|
| Fatty Acid Synthases | 1 | 2008 | 6 | 0.020 |
Why?
|
| Lipase | 1 | 2008 | 10 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 1986 | 12 | 0.020 |
Why?
|
| PPAR alpha | 1 | 2008 | 9 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 36 | 0.020 |
Why?
|
| Triglycerides | 1 | 2008 | 58 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2008 | 51 | 0.020 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 1985 | 4 | 0.020 |
Why?
|
| Pituitary Gland, Posterior | 2 | 1984 | 3 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2008 | 59 | 0.020 |
Why?
|
| Perfusion | 1 | 1987 | 8 | 0.020 |
Why?
|
| Orchiectomy | 1 | 1987 | 8 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 1987 | 8 | 0.020 |
Why?
|
| Antibodies | 1 | 1987 | 16 | 0.020 |
Why?
|
| Neuropeptides | 1 | 1987 | 6 | 0.020 |
Why?
|
| Immunization | 1 | 1986 | 19 | 0.020 |
Why?
|
| gamma-Globulins | 1 | 1985 | 1 | 0.010 |
Why?
|
| Restraint, Physical | 1 | 1985 | 3 | 0.010 |
Why?
|
| Arginine Vasopressin | 1 | 1985 | 46 | 0.010 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1985 | 21 | 0.010 |
Why?
|
| Lipids | 1 | 2005 | 35 | 0.010 |
Why?
|
| Apomorphine | 1 | 1984 | 2 | 0.010 |
Why?
|
| Pituitary Hormones | 1 | 1984 | 1 | 0.010 |
Why?
|
| Prevalence | 1 | 2005 | 259 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1984 | 25 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 145 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 1983 | 15 | 0.010 |
Why?
|
| Glutamates | 1 | 1983 | 1 | 0.010 |
Why?
|
| Sodium Glutamate | 1 | 1983 | 2 | 0.010 |
Why?
|
| Arcuate Nucleus of Hypothalamus | 1 | 1983 | 10 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 506 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 35 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1995 | 47 | 0.010 |
Why?
|
| Feedback | 2 | 1985 | 12 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1989 | 19 | 0.000 |
Why?
|
| Pulsatile Flow | 1 | 1987 | 1 | 0.000 |
Why?
|
| Naloxone | 1 | 1987 | 22 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1987 | 26 | 0.000 |
Why?
|
| Adjuvants, Immunologic | 1 | 1987 | 9 | 0.000 |
Why?
|
| Homeostasis | 1 | 1987 | 40 | 0.000 |
Why?
|
| Injections | 1 | 1986 | 20 | 0.000 |
Why?
|
| Ether | 1 | 1985 | 2 | 0.000 |
Why?
|
| Hot Temperature | 1 | 1985 | 9 | 0.000 |
Why?
|
| Epinephrine | 1 | 1985 | 9 | 0.000 |
Why?
|
| Proteins | 1 | 1985 | 41 | 0.000 |
Why?
|
| Cattle | 1 | 1984 | 13 | 0.000 |
Why?
|
| Motilin | 1 | 1984 | 1 | 0.000 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 1984 | 8 | 0.000 |
Why?
|
| Oxytocin | 1 | 1984 | 6 | 0.000 |
Why?
|
| Morphine | 1 | 1983 | 47 | 0.000 |
Why?
|